<DOC>
	<DOC>NCT02790073</DOC>
	<brief_summary>To evaluate the effect of SNF472 on top of standard of care on promoting wound healing and other parameters of therapeutic response in haemodialysis patients with calciphylaxis (calcific uraemic arteriolopathy, CUA).</brief_summary>
	<brief_title>Phase 2 Study With SNF472 in Calciphylaxis Patients</brief_title>
	<detailed_description />
	<mesh_term>Calciphylaxis</mesh_term>
	<criteria>1. Patients with newly diagnosed CUA (diagnosed within 5 weeks of study start) 2. Patients who signed the written informed consent to participate in this clinical trial (prior to any clinical trialrelated procedures being performed), after reading the Patient Information Sheet and Informed Consent Form (ICF), and who had the opportunity to discuss the clinical trial with the Investigator or designee 3. Males or females aged â‰¥18 4. Patients on maintenance haemodialysis 5. Patients with at least a minimum level of pain on VAS scale or on painkillers stronger than NSAIDs 6. Females of childbearing potential should use a highly effective contraceptive measure throughout the study AND have a negative serum pregnancy test at entry. Male patients having sexual relationship in which pregnancy can occur should take adequate contraceptive precautions (wear a condom) 1. Body weight above 150 kg 2. BMI &gt;35 and central(abdominal) ulcers 3. History of bisphosphonate treatment within 12 months before entering into the study 4. Severely ill patients without reasonable expectation of survival for &gt; 6 months according to the treating physician 5. Patients with scheduled parathyroidectomy during the runin or study period 6. Female patients who are either intending to get pregnant or are undergoing treatment to get pregnant, as well as breastfeeding females 7. Participation in another clinical trial with an experimental drug within 90 days prior the inclusion 8. Any psychological, emotional problems, any disorders or resultant therapy that is likely to invalidate informed consent, or limit the ability of the patient to comply with the Clinical Trial Protocol requirements 9. Patients who, in the opinion of the Investigator, are considered unsuitable for any other reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Calciphylaxis</keyword>
	<keyword>Calcific Uremic Arteriolopathy</keyword>
	<keyword>Dialysis</keyword>
	<keyword>End Stage Renal Disease</keyword>
	<keyword>Rare disease (ORPHA280062)</keyword>
	<keyword>Calcification</keyword>
	<keyword>Calcium Metabolism Disorders</keyword>
	<keyword>Calcinosis</keyword>
	<keyword>Metabolic Diseases</keyword>
</DOC>